About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2025 Clareo Health. All rights reserved.

Active Not RecruitingPhase 1/2

Efficacy and Safety of Chidamide in CBF Leukemia

NCT03031262•Institute of Hematology & Blood Diseases Hospital, China

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

AML

Interventions

Cytarabine

Chidamide

Locations

1

China

Locations (1)

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality, China

Key Dates

Start Date

February 8, 2017

Primary Completion Date

April 10, 2025

Completion Date

December 30, 2027

Last Updated

May 30, 2025

Related Studies

RECRUITINGPhase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT06859424

AML (Acute Myelogenous Leukemia)Acute Lymphoid Leukemia (ALL)+9 more

RECRUITINGPhase 1

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676

High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)+2 more

Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors

NCT07450872

CancerGlioma+1 more

RECRUITINGPhase 1/2

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

NCT06158828

AML, ChildhoodAml+2 more

Familial Investigations of Childhood Cancer Predisposition

NCT03050268

Acute LeukemiaAdenomatous Polyposis+44 more

RECRUITINGPhase 1/2

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

NCT07148180

Acute Myeloid Leukaemia (AML)Leukemia+2 more

View all related studies

Sponsors

Lead Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 30, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions